BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 15, 2024
See today's BioWorld
Home
» Untamed Impala: Molgradex phase III fizzles in orphan lung disease; Savara stock plunges
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Untamed Impala: Molgradex phase III fizzles in orphan lung disease; Savara stock plunges
June 14, 2019
By
Lee Landenberger
No Comments
Savara Inc.'s stock (NASDAQ:SVRA) plummeted 75.2% Thursday as top-line data from Impala, the phase III trial of Molgradex, showed the study failed to meet its primary endpoint in rare lung disease autoimmune pulmonary alveolar proteinosis.
BioWorld